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Available online 8 February 2014Erythropoietin receptor (EPOR) expression level determines the extent of erythropoietin (EPO) response.
Previously we showed that EPOR expression in endothelial cells is increased at low oxygen tension and that
EPO stimulation of endothelial cells during hypoxia can increase endothelial nitric oxide (NO) synthase (eNOS)
expression and activation aswell as NO production.We now observe that while EPO can stimulate NO production,
NO in turn can regulate EPOR expression. Human umbilical vein endothelial cells (HUVEC) treatedwith 10–50 μM
of NO donor diethylenetriamine NONOate (DETANO) for 24 h showed significant induction of EPOR gene expres-
sion at 5% and 2% of oxygen. Also human bone marrowmicrovascular endothelial cell line (TrHBMEC) cultured at
21 and 2% oxygenwith 50 μMDETANO demonstrated a time and oxygen dependent induction of EPORmRNA ex-
pression after 24 and 48 h, particularly at low oxygen tension. EPOR protein was also induced by DETANO at 2%
oxygen in TrHBMEC andHUVEC. The activation of signaling pathways byNOdonor stimulation appeared to be dis-
tinct from EPO stimulation. In reporter gene assays, DETANO treatment of HeLa cells at 2% oxygen increased EPOR
promoter activity indicated by a 48% increase in luciferase activity with a 2 kb EPOR promoter fragment and a 71%
increase in activitywith aminimal EPORpromoter fragment containing 0.2 kb 5′.We found that DETANOactivated
MAPK kinase in TrHBMEC both in normoxia and hypoxia, whileMAPK kinase inhibition showed significant reduc-
tion of EPORmRNA gene expression at low oxygen tension, suggestingMAPK involvement in NOmediated induc-
tion of EPOR. Furthermore, DETANO stimulated Akt anti-apoptotic activity after 30 min in normoxia, whereas it
inhibited Akt phosphorylation in hypoxia. In contrast, EPO did not significantly increase MAPK activity while
EPO stimulated Akt phosphorylation in TrHBMEC in normoxia and hypoxia. These observations provide a new ef-
fect of NO on EPOR expression to enhance EPO response in endothelial cells, particularly at low oxygen tensions.
© 2014 Elsevier Inc. All rights reserved.Introduction
Erythropoietin (EPO), expressed in renal peritubular cells, is secreted
into the circulation and targets EPO receptor (EPOR) expressing erythroid
progenitor cells in the bone marrow. EPO binding to EPOR on erythroid
progenitor cells activates Janus tyrosine kinase 2 (JAK2)/signal transducer
and activator of transcription 5 (STAT5), phosphatidylinositol-3 kinase
(PI-3K)/Akt, and RAS/mitogen-activatedprotein kinase (MAPK) signaling
pathways. In addition to EPO/EPOR activity in the erythroid system, EPOR
is also expressed in other tissues including neuronal cells andbrain, endo-
thelial cells and the cardiovascular system, female reproductive organs,
and the gut (Noguchi et al., 2008). Similar signal transduction pathways
have been observed in response to EPO stimulation in erythroid andiabetes and Metabolic Diseases,
Serbia, Dr. Subotica 13, 11000
ghts reserved.non-erythroid tissues. In addition, EPO enhanced NO bioavailability
through eNOS transcription and activation (Beleslin-Cokic et al., 2004).
We observed that hypoxia and EPO increased EPOR gene expression
and protein level in the vein, artery and microvascular endothelial cells
(Beleslin-Cokic et al., 2004, 2011). In addition, EPO dose- and time-
dependently stimulated NO production (Beleslin-Cokic et al., 2011). In
accordance with NO activation of soluble guanosine cyclase to produce
cyclic guanosine monophosphate (cGMP), we observed that EPO
induced cGMPproduction. These results suggested that lowoxygen ten-
sion increases endothelial cell capacity to produce NO in response to
EPO by induction of both EPOR and eNOS (Beleslin-Cokic et al., 2004).
Interestingly, in neuronal cells, NO donor increased EPOR expression
as well as EPOR promoter activity in a reporter gene assay, which
gives rise to protection against hypoxia even in the absence of exoge-
nous Epo (Chen et al., 2010).
It has been demonstrated that NO, as well as hypoxia, elevated
serum levels of EPO in ex-hypoxic polycythemic mice, while EPO dem-
onstrated NOS-dependence in stimulation of cGMP levels in hypoxia
(Ohigashi et al., 1993). In addition, non specific NOS inhibitor L-NAME
inhibited Epo production in anemic mice (Tarumoto et al., 2000). NO
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itor cells (EPCs), with endothelial properties. Epo signalingmediated via
binding to EPOR induced Akt/eNOS phosphorylation and NO synthesis
on EPCs, with an antiapoptotic action, and averted abnormal remodel-
ing of the injured carotid artery (Urao et al., 2006: d'Uscio et al.,
2007). eNOS has also a major role in EPOmediated vascular protection;
EPO activation of EPOR increased expression of phosphorylated
Ser1177-eNOS and normalized the vasodilator reaction to acetylcholine
(d'Uscio et al., 2007). Interestingly, the role of hypoxia inducible factor
(HIF) in cardiac stress response including hypoxia preconditioning
and ischemia-reperfusion injury is associated with the induction of
cardioprotective molecules, such as inducible NOS and EPO, that
improve myocardial damages (Tekin et al., 2010).
We now examine the contribution of NO on EPOR expression and
related signaling pathways in endothelial cells. To determine the
relationship of EPOR gene to NO stimulation, NO donor was used
to induce mRNA and protein level of EpoR in primary human endo-
thelial cells of vein (HUVEC) and cells from a human bone marrow
microvascular endothelial cell (TrHBMEC) cultured at normoxia
and at reduced oxygen level, that may be experienced physiological-
ly or pathologically. Reporter gene assays suggested that the
increase in EPOR expression by NO donor treatment is mediated in
part by stimulated EPOR promoter activity in hypoxia. NO stimula-
tion in hippocampal slices was associated with MAPK activation
(Kanterewicz et al., 1998) and we determined that NO also stimulat-
ed MAPK signaling pathway both in normoxia and hypoxia in endo-
thelial cells. Also, treating endothelial cells with MAPK inhibitor
significantly reduced EPOR mRNA expression after stimulation
with NO donor particularly at low oxygen tension. While NO
inhibited Akt signaling pathway in hypoxia, we found that EPO
triggered anti-apoptotic Akt signaling pathway in normoxia and in
early response to hypoxia. Therefore, these signal transduction
pathways in response to NO are distinct from EPO response.Fig. 1.NO stimulated EPORmRNA expression in endothelial cells. A) EPOR expressionwas
normalized to β-actin expression in TrHBMEC during treatmentwith 50 μMof DETANO at
2% and 21%O2 after 3, 24 and 48 h of incubation. B) EPOR expressionwas normalized to β-
actin expression in HUVEC during treatment with 10, 25 and 50 μM of DETANO at 2%, 5%
and 21% O2 after 24 h of incubation. Values are mean± SEM (n= 3). *p b 0.05, **p b 0.01
and ***p b 0.001 vs. controls.Materials and methods
Cell cultures
Human umbilical vein endothelial cells (HUVECs; Clonetics,
Walkersville, MD) and transformed human bone marrow endothelial
cells (TrHBMECs) were grown as previously described (Beleslin-Cokic
et al., 2004). Briefly, HUVECs were cultured in endothelial basal media
(EBM-2) containing 2% fetal bovine serum (FBS) and cytokines
under 5% of CO2. TrHBMECs were grown in Dulbecco modified
Eagle medium (DMEM) with 10% FBS in 5% CO2. Human cervical
adenocarcinoma (HeLa) cells were cultured in DMEM, containing
penicillin–streptomycin, 10% FBS under 5% CO2 with balanced 95%
room air. All cells were cultured in a humidified atmosphere at 37 °C
(Forma Scientific, Marietta, OH). Before exposure to reduced oxygen,
TrHBMECs were trypsinized, washed and cultured in DMEM medium.
HUVECs were washed in HEPES (N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid) buffer and plated in EBM-2 containing 2% FBS
and cytokines, and cultured at low oxygen tension (5% or 2% O2).
When confluent, the endothelial cells were treated with 10–50 μM
NO donor diethylenetriamine NONOate (DETANO, Alexis Biochemi-
cals, San Diego, CA) and EPO, with or without MAPK inhibitor,
PD98059 (Cell Signaling Technology, Danvers, MA), at different oxy-
gen tensions (2, 5 and 21% O2). DETANO is a NO donor with a half-life
of 20 h at 37 °C. Following incubation cells were washed once with
PBS or HEPES buffer. For investigating the role of MAPK signaling
on NO induction of EPOR, TrHBMECs were cultured in 10% FBS
DMEM for 48 h either at 2% or 21% O2. When cells reached 90% con-
fluence, 50 μM of MAPK inhibitor was added to the culture for one
hour, then washed with PBS and cultured in media with 50 μM
DETANO for an additional 24 h.Quantitative real-time RT-polymerase chain reaction analyses
After incubation at different oxygen tensions, endothelial cells were
harvested. RNAwas isolated using STAT 60 (Tel-TEST, Friendswood, TX)
and treatedwith RNase-Free DNase (Promega,Madison,WI). Total RNA
from each sample was used for first-strand cDNA synthesis using
reverse transcriptase and oligo d(T)16 (Applied Biosystems, Foster
City, CA). Quantitative real-time RT-polymerase chain reaction (PCR)
analyses were performed using a 7700 or 7900 Sequence Detector
and Taqman EPOR oligonucleotide probes and primers (Applied
Biosystems) as previously described (Beleslin-Cokic et al., 2004).
β-Actin was used as an internal control for the total amount of
RNA analyzed.Protein analysis
Endothelial cells were treatedwith lysis buffer and scraped from the
plate. For measurement of protein concentration in examined samples
we used a copper chelation procedure and bicinchoninic acid colorimet-
ric assay (BCA Protein Assay Reagent, Pierce, Rockford, IL). For EPOR
analysis, 1 mg protein was incubated with EPOR rabbit polyclonal anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA) at 4 °C overnight. The
immunocomplex was captured by adding protein A–Agarose (Santa
Cruz Biotechnology), agitated at 4 °C for 2 h, centrifuged, and the
Fig. 2.NOstimulated EPORprotein expression in endothelial cells. A–D)Analysis byWestern blotting for EPORat 2% and 21%of oxygen (A andC)wasnormalized to control value (B andD)
during treatment with 50 μM of DETANO after 3, 6 and 24 h of incubation for TrHBMEC (A and B) and during treatment with 25 and 50 μM of DETANO after 6 h of incubation for
HUVEC (C and D). OCIM-1 cell extract was used as positive control. E) Two hEPOR reporter gene constructs (hEPOR −1778 and hEPOR −194) were assessed with and without
50 μM DETANO treatment in HeLa cells at 2% O2 after 24 h of treatment. Values are mean ± SEM (n = 3). *p b 0.05 and **p b 0.01 vs. controls.
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sample was separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a nitrocellulose mem-
brane. The membrane was blocked with 5% milk–0.1% Tween 20 for 1
h at room temperature and probed with EPOR rabbit polyclonal anti-
body overnight at 4 °C. Horseradish peroxide-labeled anti-rabbit immu-
noglobulin G (IgG) was used as the secondary antibody. Hyperfilm was
used to visualize the secondary antibody by enhanced chemilumines-
cence (ECL; Amersham Pharmacia Biotech, Piscataway, NJ). For analysis
ofMAPK and Akt phosphorylation, cells werewashedwith cold PBS, left
in serum-free media for 6 h, and treated with EPO and DETANO for
15 min, 30 min and 1 h, with or without MAPK inhibitor PD98059
(50 μM). Then, they were lysed and proteins were incubated with
phosphoMAPK/MAPK and phosphoAkt/Akt antibody (Cell Signaling
Technology) overnight. Cells were washed with HEPES, treated with
lysis buffer and scraped from the plate. The proteins were separated
by SDS-PAGE and transferred to a nitrocellulose membrane. The mem-
brane was probed using as a primary antibody for phosphorylated
MAPK and Akt antibody (Cell Signaling Technology) and incubated at4 °C overnight. The labeled phosphorylated MAPK and Akt was visual-
ized by chemiluminescence. Membrane was then stripped for 1 h at
55 °C, washed, blocked, and incubated with MAPK and Akt antibody
overnight at 4 °C and then visualized by chemiluminescence for assess-
ment of total MAPK and Akt.
EPOR reporter gene transfection and activity assay
EPOR reporter gene constructs consisted of the 5′ untranslated tran-
scribed region (UTR) flanking the EPOR coding region and extending to
−1778 and −194 bp 5′ of the transcription start site inserted into the
pGL3-basic (Promega, Madison, WI) luciferase reporter construct were
cotransfected with a control Renilla luciferase construct (pRL-TK) into
HeLa cells with Lipofectamine™ 2000 (Invitrogen). Transfected HeLa
cells were treated with 50 μM DETANO and incubated at 2% or 21% O2.
After 24 h, cells were harvested, and the activity of the EPOR reporter
gene was determined by the Dual Luciferase Assay System (Promega).
A promoterless construct containing only the 5′ UTR beginning at +3
of EPOR linked to luciferase was used as a negative control.
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The one-way analysis of variance (ANOVA) and Dunnett's post tests
were applied using Prism 4 software (GraphPad Software Inc., San
Diego, CA).
Results
Nitric oxide and hypoxia increase EPOR gene expression in endothe-
lial cells.
We previously reported that hypoxia increased EPOR gene expres-
sion in TrHBMEC and lung microvascular endothelial cells (Beleslin-
Cokic et al., 2004, 2011). We now show that NO was also able to affect
EPOR expression in endothelial cells. DETANO treatment of TrHBMEC
resulted in an increase of EPOR expression at 24 to 48 h of incubation
depending on oxygen tension (Fig. 1a). At 24 h, DETANO combined
with hypoxia stimulated EPOR gene expression in TrHBMEC. After 48Fig. 3. NO stimulated MAPK phosphorylation (pMAPK) in endothelial cells. A–F) Determinat
TrHBMEC treated with 50 μM of DETANO up to 60 min at 2% and 21% O2 (A–B) and for treat
MAPK inhibitor PD98059 (PD) at 21% O2 (C–D) and at 2% O2 (E–F). Values are mean ± SEM (nh of treatment, induction of EPOR gene expression byDETANO and hyp-
oxia increased, and was also increased to a lesser extent at normoxia
(Fig. 1a). In addition, we demonstrated a dose dependent induction of
EPOR gene expression by DETANO in HUVECs both at 2% and 5% O2
following 24 h of incubation, but not at 21% O2 (Fig. 1b). Examination
of EPOR protein production in endothelial cells revealed that DETANO
stimulated EPOR protein expression in hypoxia but not at normoxia in
TrHBMEC (Figs. 2a–b). In HUVECs, EPOR protein was also induced by
DETANO (by three fold) at 50 μM with hypoxia, but no induction was
observed at a lower dose of DETANO at 25 μM (Figs. 2c–d).
EPOR reporter gene assay
We used EPOR promoter reporter genes to determine if NO contrib-
utes to the regulation of EPOR expression at the transcription level. The
EPOR promoter-luciferase reporter gene construct, containing 2 kb
promoter fragment that includes the 5′ UTR and extending upstreamion by Western blotting of pMAPK (p42,44) was normalized to total MAPK (p42,44) in
ment without and with EPO (5U/ml), without and with DETANO, and without and with
= 3). *p b 0.05, **p b 0.01 vs. controls. ***p b 0.001 vs. samples before treatment.
Fig. 4. NO stimulation of EPOR gene expression is MAPK dependent. A–B) Determination
of EPORmRNAexpression in TrHBMECwasnormalized toβ-actin expression during treat-
ment with 50 μM of DETANO without or with 50 μM MAPK inhibitor PD98059 at 21% O2
(A) and 2% O2 (B) after 24 h of incubation. Values are mean ± SEM (n = 3). *p b 0.05
and **p b 0.01 vs. controls.
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HeLa cells. DETANO treated HeLa cells increased luciferase activity 48%
at 2% oxygen for the 2 kb EPOR promoter construct after 24 h of incuba-
tion at hypoxia (Fig. 2e). Interestingly, truncation of the promoter frag-
ment from −1778 bp 5′ to −198 bp 5′ showed a greater increase of
luciferase activity with DETANO treatment by 71%. These results were
consistent with the EPOR gene expression data and suggest that NO
contributed to the induction of EPOR expression in hypoxia in part at
the transcription level. Treatment of the transfected HeLa cells with
the NO donor in normoxia did not change the EPOR promoter activity
(not shown).
Nitric oxide but not EPO activates MAPK signaling pathway
It has been reported that NO donors augmented the active forms
of both p42MAPK and p44MAPK (Kanterewicz et al., 1998). DETANO
significantly stimulated activation of p42 MAPK and p44 MAPK both
in hypoxia and in normoxia in TrHBMECs during the first 60 min
(Figs. 3a, b). In contrast, EPO failed to induce significant MAPK phos-
phorylation in hypoxia and normoxia (Figs. 3c–f). Phosphorylation
of p42/44 MAPK in TrHBMECs stimulated with DETANO or EPO was
decreased by anorder ofmagnitude ormorewithin 30min of treatment
with the MAPK inhibitor PD98059 at both in hypoxia and normoxia
(Figs. 3d, f).
Nitric oxide and hypoxia increase of EPOR gene expression is MAPK
dependent
MAPK activation by DETANO (Fig. 3) and the relationship between
DETANO and EPOR gene expression raised the possibility that MAPK
mediates the change in EPOR expression. Although DETANO did not in-
duce significant EPORmRNAexpression at 21%O2 in TrHBMEC (Fig. 4a),
DETANO treatment almost doubled EPOR gene expression at 2%O2 after
24 h of incubation (Fig. 4b). This NO donor stimulation of EPOR gene
expression was prevented by MAPK inhibitor PD98059. Therefore, NO
stimulation of EPOR is partlymediated byMAPK signaling pathwaydur-
ing hypoxia. In contrast, activation of MAPK at normoxia is insufficient
to induce EPOR expression.
Nitric oxide inhibits while EPO activates Akt signaling pathway in hypoxia
Akt has downstream anti-apoptotic effectswhen activated by growth
factors through PI-3K. It has been reported that serine/threonine protein
kinase Aktmediated the activation of eNOS, leading to increasedNOpro-
duction (Dimmeler et al., 1999). On the other hand, NO donors increased
PI-3K regulated Akt phosphorylation and activity in endothelial cells
(Kawasaki et al., 2003). EPO also stimulated Akt phosphorylation in
normoxia (Akimoto et al., 2000). To compare EPO and DETANO effects
on Akt signaling, we found that EPO stimulated Akt phosphorylation
within 15min in normoxia andhypoxia in TrHBMECs (Figs. 5a–b).More-
over, we observed time-dependent effects of EPO during incubation and
Akt phosphorylation decreased to baseline levels or lower by 60 min. A
time dependent response is also observed with DETANO incubation.
DETANO stimulated Akt activity after 30min in normoxia that decreased
toward base line level at 60 min. However, in contrast to EPO, DETANO
inhibited Akt phosphorylation in hypoxia throughout the incubation pe-
riod of 60 min (Figs. 5c–d).
Discussion
We previously described the stimulation of EPOR expression, eNOS
activity and elevated NO production by hypoxia and EPO in endothelial
cells (Beleslin-Cokic et al., 2004, 2011). Here we show that a NO donor
stimulated EPOR gene expression and protein production in TrHBMEC
andHUVEC, particularly at reduced oxygen tension. In reporter gene as-
says, NO donor treatment increased EPOR promoter activity at 2%oxygen. In TrHBMEC, NO donor stimulated activation of p42/p44
MAPK and EPOR gene expression. The induction of EPOR by NO was
prevented by MAPK inhibitor. NO donor transiently stimulated Akt ac-
tivity in normoxia, but inhibited Akt phosphorylation in hypoxia in
TrHBMEC. These changes in signal transduction with NO treatment are
in contrast to EPO response. EPO did not induce MAPK phosphorylation
in hypoxia and normoxia, but stimulated Akt phosphorylation in
normoxia and hypoxia in TrHBMEC.
We and others provide increasing evidence of EPO activity in vascu-
lar endothelium resulting in NO production. We previously reported
that EPO stimulated the phosphorylation of eNOS and increased pro-
duction of NO and cGMP during hypoxia (Beleslin-Cokic et al., 2004).
Moreover, hypoxia and EPO increased EPOR gene expression and pro-
tein level, as well as eNOS gene expression (Beleslin-Cokic et al., 2004,
2011). Other studies provided additional evidence of EPO induction of
NO. EPO treatment increased NOS activity in endothelial cells of the
human coronary artery, pulmonary artery and dermis (Banerjee et al.,
2000). Transgenic mice expressing high level of EPO have elevated
eNOS protein expression in vascular endothelium and elevated NO
levels in the circulation (Ruschitzka et al., 2000). Furthermore, the
phosphorylation of eNOS was significantly higher in aorta from EPO
transgenic mice than wild-type mice (Su et al., 2012). Transduction of
basilar arteries with EPO increased the eNOS protein expression and
stimulated eNOS phosphorylation at serine 1177. Basal levels of cGMP
were significantly elevated in arteries transduced with EPO, consistent
with increased NO production (Santhanam et al., 2006). The observa-
tions presented here that NO also stimulates EPOR expression further
link NO to EPO activity at hypoxic conditions, likely contributing to en-
dothelial cell stability andmicrovasculature integrity inmaintenance of
blood pressure.
Hypoxia has been related to both the upregulation and downregula-
tion of steady-state eNOS mRNA expression. Therefore, it is not unex-
pected that endothelial cells from various vascular beds react to
Fig. 5. Phosphorylation of Akt by NO and EPO in endothelial cells. A–D) Determination of pAkt was normalized to total Akt in TrHBMEC during 60 min of treatment with 5U/ml of
EPO (A–B) and 50 μM of DETANO (C–D) at 21% and 2% of oxygen. Values are mean ± SEM (n = 3). *p b 0.05 and **p b 0.01vs. untreated cells.
39B.B.B. Cokic et al. / Microvascular Research 92 (2014) 34–40hypoxia in different ways (Tai et al., 2004). Early reports suggested
decreasedNOS activity in the presence of low oxygen tensions in bovine
endothelial cells (Liao et al., 1995; Phelan and Faller, 1996). However, it
was subsequently demonstrated that NO generation is enhanced on
hypoxia exposure both in bovine (Chen et al., 2008; Presley et al.,
2008) and human endothelial cells (Coulet et al., 2003). Moreover, ex-
ogenous hypoxia-inducible factor (HIF)-2, as well as hypoxia, markedly
increased luciferase reporter activity driven by the eNOS promoter
(Arnet et al., 1996; Coulet et al., 2003). In neural cell cultures addition
of NO donor to cultures, grown under normoxia and hypoxia, induced
EPOR expression. Hypoxia increased NO production as well as EPOR ex-
pression, and inhibition of nNOS activity reduced the proportion of
EPOR-expressing neurons induced at low oxygen. Conversely, addition
of NO donor to cultures grown under normoxia induced EPOR (Chen
et al., 2010). In the present study, we demonstrated that in endothelial
cells under hypoxic condition NO stimulated EPOR gene expression
both at mRNA and protein levels. Furthermore, NO donor increased
EPOR promoter activity in a reporter gene assay under hypoxia, but
not under normoxia, suggesting that NO regulated EPOR at the tran-
scription level in reduced oxygen conditions. During ischemia or hypox-
ic stress, NO induction of blood vessel vasodilation would increase
delivery of oxygenated blood to hypoxic tissue, while hypoxia induced
EPO would promote erythropoiesis to increase the oxygen carrying
capacity of blood. The potential of EPO to stimulate NO production by
endothelial cells and the apparent feedback of NO to increase EPOR to
facilitate an EPO response would further contribute to regulation of
vascular tone and facilitate oxygen delivery.
Endogenous NO generation promoted activation of the p42/p44
MAPK. NO affected p42/p44 MAPK by cGMP mediated rapid activation,
while late activation was transmitted via inhibition of tyrosine dephos-
phorylation (Callsen et al., 1998). Here we show that NO stimulated ac-
tivation of p42/p44 MAPK, and that NO stimulation of EPOR gene
expression in hypoxia was MAPK dependent. These data indicate that
MAPK activation is necessary but not sufficient for NO induction of
EPOR, becauseNO activatesMAPK in both normoxia and hypoxia, but in-
duces EPORonly at hypoxia.Moreover, NOhas been reported tomarked-
ly decreased Akt activation, while overexpression of constitutively activeAkt reduced NO-induced apoptosis (Sang et al., 2011;Wang et al., 2007).
The serine/threonine protein kinase Akt can directly phosphorylate
eNOS on serine 1179 and activate the enzyme, leading to NO production
(Fulton et al., 1999). In the present results, NO stimulated transient Akt
activity in normoxia, but inhibited Akt phosphorylation in hypoxia in en-
dothelial cells. Signal transduction response to NOwas distinct from EPO
response, as EPO stimulated short termAkt phosphorylation in normoxia
and hypoxia in TrHBMEC.
Taken together, our presented data suggest that NO response at low
oxygen tension results in upregulated EPOR gene expression accompa-
nied by stimulation of the p42/p44 MAPK and inhibition of Akt phos-
phorylation in endothelial cells. Induction of EPOR by NO could
potentially form a positive feedback mechanism for eNOS activation
by EPO in endothelial cells at low oxygen tension, while NO inhibited
Akt activation in hypoxia. Variation in NO response relating to endothe-
lial cell tissue origin may further contribute to a corresponding variabil-
ity in EPO response. These results provide further support for an
important role of the NO/cGMP system in hypoxic regulation of EPO
production, participating in pathogenesis of anemia, repair of injured
endothelium, hypertension and ischemia-reperfusion injury.
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